Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

Baron Health Care Fund stated the following regarding Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in its Q3 2024 investor letter: “We purchased Regeneron Pharmaceuticals, Inc. (NASDAQ ...

“Capital letters are very nice,” said Michael Beirut, a graphic designer and partner at New York-based Pentagram Design, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project. The two companies, along with 17 US health ...

When the FDA turned down odronextamab in a complete response letter in March, Regeneron said that it was because it had not yet started trials that would be used to confirm accelerated approvals ...